Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

Imeglimin is an investigational first‐in‐class novel oral agent for the treatment of type 2
diabetes (T2D). Several pivotal phase III trials have been completed with evidence of …

Diabetic kidney disease (DKD) is one of the most frequent causes of chronic kidney disease
(CKD) in the United States. Chronic hyperglycemic conditions are thought to be the primary …

Imeglimin is a new anti-diabetic drug commercialized in Japan (Twymeeg®) and has been
drawing much attention in diabetes research area as well as in clinical practice. In this study …

The pathogenesis of heart failure with preserved ejection fraction (HFpEF) in obese diabetic
patients has been implicated in metainflammation. Increased expression of inducible nitric …

Diabetic kidney disease (DKD) is a severe and common complication and affects a quarter
of patients with type 2 diabetes mellitus (T2DM). Oxidative stress and inflammation related to …

Diabetes mellitus (DM) is a chronic, progressive, and multifaceted illness resulting in
significant physical and psychological detriment to patients. As of 2019, 463 million people …

The effects of imeglimin, a novel antidiabetes agent, on β-cell function remain unclear. Here,
we unveiled the impact of imeglimin on β-cell survival. Treatment with imeglimin augmented …

Introduction Endothelial dysfunction is a risk factor for cardiovascular disease in patients
with diabetes. We hypothesized that imeglimin, a novel oral hypoglycemic agent, would …

Simple Summary Mitochondria are organelles found in the cells of animals. Mitochondria
use aerobic respiration to generate adenosine triphosphate. Mitochondrial dysfunction is a …